Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,823 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA Jr, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG. Laubach JP, et al. Among authors: desai a. Br J Haematol. 2017 Aug;178(4):547-560. doi: 10.1111/bjh.14708. Epub 2017 May 3. Br J Haematol. 2017. PMID: 28466536 Free PMC article.
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P. Sonneveld P, et al. Among authors: desai a. J Clin Oncol. 2013 Sep 10;31(26):3279-87. doi: 10.1200/JCO.2012.48.4626. Epub 2013 Jul 29. J Clin Oncol. 2013. PMID: 23897961
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Mateos MV, Bringhen S, Richardson PG, Lahuerta JJ, Larocca A, Oriol A, Boccadoro M, García-Sanz R, Di Raimondo F, Esseltine DL, van de Velde H, Desai A, Londhe A, San Miguel JF, Palumbo A. Mateos MV, et al. Among authors: desai a. Haematologica. 2014 Jun;99(6):1114-22. doi: 10.3324/haematol.2013.099341. Epub 2014 Apr 24. Haematologica. 2014. PMID: 24763402 Free PMC article.
Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.
Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R, Mehra M. Usmani S, et al. Among authors: desai a. Oncologist. 2016 Nov;21(11):1355-1361. doi: 10.1634/theoncologist.2016-0104. Epub 2016 Aug 2. Oncologist. 2016. PMID: 27486203 Free PMC article.
Phase I study of adavosertib with radiation therapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma.
Lee EQ, Alexander BM, Romo CG, Supko JG, Agar NYR, Talebi Z, Ahluwalia MS, Desai AS, Dietrich J, Kaley TJ, Peereboom DM, Gantchev J, Baquer G, Santagata S, Takebe N, Desideri S, Fisher JD, Sims M, Ye X, Ligon KL, Nabors LB, Grossman SA, Wen PY. Lee EQ, et al. Among authors: desai as. Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-2311. Online ahead of print. Clin Cancer Res. 2025. PMID: 39820282
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.
Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Viswanathan P, Kolkhof P, Schloemer P, Amarante F, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV; FINEARTS-HF Committees and Investigators. Butt JH, et al. Among authors: desai as. Lancet Diabetes Endocrinol. 2025 Jan 13:S2213-8587(24)00309-7. doi: 10.1016/S2213-8587(24)00309-7. Online ahead of print. Lancet Diabetes Endocrinol. 2025. PMID: 39818225
Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.
Matsumoto S, Jhund PS, Henderson AD, Bauersachs J, Claggett BL, Desai AS, Brinker M, Schloemer P, Viswanathan P, Mares JW, Scalise A, Lam CSP, Linssen GCM, Kerr Saraiva JF, Senni M, Troughton R, Udell JA, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Matsumoto S, et al. Among authors: desai as. J Am Coll Cardiol. 2025 Jan 21;85(2):173-185. doi: 10.1016/j.jacc.2024.11.020. J Am Coll Cardiol. 2025. PMID: 39814476 Clinical Trial.
3,823 results